Epstein-Barr virus neutralizing and early antigen antibodies in multiple sclerosis.
BACKGROUND
Our objective was to determine whether antibodies against the Epstein-Barr virus (EBV) nuclear antigen-1 (EBNA-1), early antigen (EA), and EBV neutralizing antibodies (NeutAb) are altered in multiple sclerosis (MS).


METHODS
We measured EBNA-1 IgG, EA IgG, and EA IgA using quantitative ELISA. We measured NeutAb using a quantitative competitive ELISA. We studied 80 patients with MS, 80 matched controls, and 19 patients with MS with samples collected both whilst stable and in relapse.


RESULTS
Epstein-Barr virus nuclear antigen-1 IgG and EA IgA were increased in MS compared to controls. The EBNA-1 index value was 23.3 ± 18.3 in the patients with MS (mean ± SD) and 16.3 ± 17.4 in the controls (P = 0.007, paired t-test). EA IgA had a median value of 1.964 in the patients with MS and 1.248 in the controls (P = 0.029, Wilcoxon signed rank test). EA IgG and NeutAb were not significantly different. None of the antibody levels were altered in relapse. The correlation between concentrations of different antibodies was minimal.


CONCLUSIONS
IgG antibodies to EBNA-1 are significantly increased in MS. IgA antibodies against EBV EA are also increased. The EBV neutralizing antibody response is similar in MS and controls.
Lindsey
J W
JW
University of Texas Health Science Center at Houston, Houston, TX 77030, USA. John.w.lindsey@uth.tmc.edu
Hatfield
L M
LM
Vu
T
T
D000328:Adult; D057134:Antibodies, Neutralizing / Q000096:biosynthesis / Q000097:blood*; D000956:Antigens, Viral / Q000276:immunology*; D020031:Epstein-Barr Virus Infections / Q000150:complications* / Q000276:immunology*; D019309:Epstein-Barr Virus Nuclear Antigens / Q000276:immunology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000150:complications / Q000276:immunology* / Q000821:virology*; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000150:complications / Q000276:immunology / Q000821:virology
D057134:Antibodies, Neutralizing; D000956:Antigens, Viral; D019309:Epstein-Barr Virus Nuclear Antigens; C033305:Epstein-Barr virus early antigen; C417029:EBV-encoded nuclear antigen 1
J Neurol Neurosurg Psychiatry. 2005 Oct;76(10):1377-81
16170080
J Neuroimmunol. 2007 Dec;192(1-2):184-5
17869349
J Virol Methods. 1998 Jul;73(1):11-9
9705170
Neurology. 2000 Jul 25;55(2):178-84
10908887
Viral Immunol. 2000;13(4):497-502
11192296
Eur J Neurol. 2008 Jan;15(1):106-8
18042233
Epidemiology. 2000 Mar;11(2):220-4
11021623
Neurology. 2006 Dec 12;67(11):2063-5
17159123
Arch Neurol. 2006 Jun;63(6):839-44
16606758
Ann Neurol. 2007 Apr;61(4):288-99
17444504
Trends Immunol. 2009 Jun;30(6):243-8
19428300
Brain. 2006 Jun;129(Pt 6):1493-506
16569670
J Neurol Neurosurg Psychiatry. 1998 Apr;64(4):539-42
9576551
Neurology. 2004 Jun 22;62(12):2277-82
15210894
J Clin Microbiol. 1999 Aug;37(8):2709-14
10405428
Proc Natl Acad Sci U S A. 1980 May;77(5):2979-83
6248876
Neurology. 1985 Mar;35(3):435-8
2983262
JAMA. 2005 May 25;293(20):2496-500
15914750
J Gen Virol. 1987 Feb;68 ( Pt 2):535-43
2434608
J Virol. 1982 Aug;43(2):730-6
6287039
Science. 1970 Jul 10;169(3941):188-90
4316788
Acta Neurol Scand. 1998 Mar;97(3):171-4
9531433
Ann Neurol. 1985 Apr;17(4):371-7
2988410
Neurology. 2008 Sep 23;71(13):1033-5
18809840
Lancet Neurol. 2007 Sep;6(9):773-81
17689148
Ann Neurol. 2006 Mar;59(3):499-503
16502434